Skip to main content
Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.

As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Sandra Davern performs cell based assays to evaluate cell death and DNA damage in response to radiation in order to gain a better understanding of how radioisotope nanoparticles affect the human body.

When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.